Functional annotation and enrichment analysis of differentially expressed serum proteins in patients with type 2 diabetes after dapagliflozin  

作　　者：Yan-Xue Zhao Sarul Borjigin Zhao-Li Yan 

机构地区：[1]Basic Building Laboratory,The Affiliated Hospital of Inner Mongolia Medical University,Hohhot 010000,Inner Mongolia,China [2]Department of Endocrinology,The Affiliated Hospital of Inner Mongolia Medical University,Hohhot 010000,Inner Mongolia,China

出　　处：《World Journal of Diabetes》2022年第3期224-239,共16页世界糖尿病杂志（英文版）（电子版）

基　　金：Supported by Major Scientific Research Program of The Affiliated Hospital of Inner Mongolia Medical University,No. NYFY ZD 001

摘　　要：BACKGROUND Only 50% of patients with type 2 diabetes mellitus(T2DM) can control their blood glucose levels. Dapagliflozin is a selective inhibitor of sodium-glucose cotransporter 2(SGLT-2) that improves the insulin sensitivity of the liver and peripheral tissues. Many studies confirmed that SGLT2 inhibitors reduce blood glucose and have multiple beneficial effects such as weight loss, lipid regulation, and kidney protection. Nevertheless, the mechanisms of the renal and cardiovascular protective effects of dapagliflozin from the perspective of differentially expressed proteins in the serum of T2DM patients have not been intensively explored so far.AIM To identify differentially expressed proteins associated with dapagliflozin treatment in patients with T2DM.METHODS Twenty T2DM patients [hemoglobin A1c(HbA1c) 7.0%-10.0%] were enrolled at The Affiliated Hospital of Inner Mongolia Medical University between January 1, 2017 and December 1, 2018. They received dapagliflozin(10 mg/d) for 3 mo, and the HbA1c < 7.0% target was achieved. The changes in clinical indexes were compared before and after treatments. Label-free quantitative proteomics was used to identify differentially expressed proteins using the serum samples of five patients. The identified differentially expressed proteins were analyzed using various bioinformatics tools.RESULTS Dapagliflozin significantly improved the clinical manifestation of the patients. There were 18 downregulated proteins and one upregulated protein in the serum samples of patients after dapagliflozin administration. Bioinformatics analyses, including subcellular localization, Eu Karyotic Orthologous Groups, Gene Ontology, and Kyoto Encyclopedia of Genes and Genomes annotations, were used to profile the biological characteristics of the 19 differentially expressed proteins. Based on the literature and function enrichment analysis, two downregulated proteins, myeloperoxidase(MPO) and alpha Ⅱ B integrin(ITGA2B), and one upregulated protein, podocalyxin(PCX), were selected for enzyme

关 键 词：Type 2 diabetes mellitus DAPAGLIFLOZIN Non-standard quantitative proteomics MYELOPEROXIDASE Alpha II B integrin PODOCALYXIN 

分 类 号：R587.1[医药卫生—内分泌]